Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYTO Altamira Therapeutics	$0.30 -25.9%	$0.36	$0.30 ▼ $1.34	$1.02M	1.8	291,465 shs	753,013 shs
DRMA Dermata Therapeutics	$5.46 +0.9%	$6.60	$5.09 ▼ $24.90	$3.71M	0.56	74,602 shs	4,981 shs
EVAX Evaxion A/S	$3.06 +3.9%	$2.64	$1.20 ▼ $17.75	$4.26M	0.13	965,786 shs	39,647 shs
JAGX Jaguar Animal Health	$1.86 -0.5%	$2.49	$1.81 ▼ $35.25	$3.55M	0.43	89,392 shs	55,727 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYTO Altamira Therapeutics	0.00%	0.00%	0.00%	0.00%	-69.07%
DRMA Dermata Therapeutics	-4.08%	-16.38%	-22.15%	-29.56%	-73.22%
EVAX Evaxion A/S	-2.96%	-2.96%	+14.79%	+57.75%	-81.68%
JAGX Jaguar Animal Health	-2.60%	-27.80%	-22.41%	-58.72%	-93.66%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CYTO Altamira Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DRMA Dermata Therapeutics	3.3423 of 5 stars	3.5	5.0	0.0	0.0	3.5	0.8	0.6
EVAX Evaxion A/S	2.4054 of 5 stars	3.5	2.0	0.0	0.0	2.1	1.7	0.6
JAGX Jaguar Animal Health	2.0249 of 5 stars	3.5	3.0	0.0	0.0	1.5	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYTO Altamira Therapeutics	0.00	N/A	N/A	N/A
DRMA Dermata Therapeutics	3.00	Buy	$10.00	83.12% Upside
EVAX Evaxion A/S	3.00	Buy	$10.00	226.37% Upside
JAGX Jaguar Animal Health	3.00	Buy	$60.00	3,125.81% Upside

Current Analyst Ratings Breakdown

Latest CYTO, EVAX, DRMA, and JAGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/21/2025	DRMA Dermata Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $10.00
5/21/2025	DRMA Dermata Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$60.00 ➝ $30.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYTO Altamira Therapeutics	$320K	3.19	N/A	N/A	$4.56 per share	0.07
DRMA Dermata Therapeutics	N/A	N/A	N/A	N/A	$8.24 per share	N/A
EVAX Evaxion A/S	$3.34M	1.28	N/A	N/A	$4.44 per share	0.69
JAGX Jaguar Animal Health	$11.69M	0.30	N/A	N/A	$2.30 per share	0.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYTO Altamira Therapeutics	-$4.31M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
DRMA Dermata Therapeutics	-$12.29M	-$16.41	N/A	∞	N/A	N/A	-214.98%	-153.76%	N/A
EVAX Evaxion A/S	-$10.57M	-$1.32	N/A	N/A	N/A	-316.03%	-319.52%	-63.56%	10/30/2025 (Estimated)
JAGX Jaguar Animal Health	-$38.49M	N/A	0.00	N/A	N/A	-344.16%	-660.18%	-77.42%	N/A

Latest CYTO, EVAX, DRMA, and JAGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	EVAX Evaxion A/S	-$0.50	-$0.76	-$0.26	-$0.76	N/A	$0.04 million
8/14/2025	Q2 2025	JAGX Jaguar Animal Health	-$7.13	-$10.26	-$3.13	-$10.26	$3.27 million	$2.98 million
8/13/2025	Q2 2025	DRMA Dermata Therapeutics	-$2.90	-$1.66	+$1.24	-$1.66	N/A	N/A
5/27/2025	Q1 2025	EVAX Evaxion A/S	-$0.65	-$0.29	+$0.36	-$0.29	$0.06 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYTO Altamira Therapeutics	N/A	N/A	N/A	N/A	N/A
DRMA Dermata Therapeutics	N/A	N/A	N/A	N/A	N/A
EVAX Evaxion A/S	N/A	N/A	N/A	N/A	N/A
JAGX Jaguar Animal Health	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYTO Altamira Therapeutics	N/A	0.43	N/A
DRMA Dermata Therapeutics	N/A	6.47	6.47
EVAX Evaxion A/S	1.73	3.42	2.01
JAGX Jaguar Animal Health	2.44	0.95	0.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYTO Altamira Therapeutics	1.91%
DRMA Dermata Therapeutics	8.67%
EVAX Evaxion A/S	11.04%
JAGX Jaguar Animal Health	12.04%

Insider Ownership

Company	Insider Ownership
CYTO Altamira Therapeutics	13.03%
DRMA Dermata Therapeutics	18.50%
EVAX Evaxion A/S	41.64%
JAGX Jaguar Animal Health	4.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYTO Altamira Therapeutics	20	3.40 million	2.96 million	Not Optionable
DRMA Dermata Therapeutics	8	680,000	556,000	Not Optionable
EVAX Evaxion A/S	60	1.40 million	819,000	No Data
JAGX Jaguar Animal Health	50	1.91 million	1.83 million	No Data

CYTO, EVAX, DRMA, and JAGX Headlines

Recent News About These Companies

Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia's Indication to Treatment of General Diarrhea in Dogs

August 21 at 9:00 AM | accessnewswire.comA

Jaguar Health, Inc.: Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders

August 20 at 9:28 PM | finanznachrichten.de

Jaguar Health Announces Promising Trial Results

August 20 at 3:07 AM | msn.com

Jaguar Health, Inc. (JAGX) Q2 2025 Earnings Call Transcript

August 19 at 4:19 PM | seekingalpha.com

Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders

August 19 at 4:15 PM | accessnewswire.comA

Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease (MVID)

August 19 at 9:00 AM | accessnewswire.comA

Jaguar Health Reports Increased Losses Amid Rising Expenses

August 15, 2025 | msn.com

Jaguar Health Extends Market Offering Agreement

August 14, 2025 | msn.com

Jaguar Health Reports Second Quarter 2025 Financials: Net Q2 2025 Revenue Up Approximately 35% Versus Net Q1 2025 Revenue

August 14, 2025 | accessnewswire.comA

Jaguar Health to Hold Investor Webcast Thursday, August 14 at 8:30 AM Eastern Regarding Q2 2025 Financials & Corporate Updates

August 12, 2025 | accessnewswire.comA

Jaguar Animal Health (JAGX) Expected to Announce Earnings on Tuesday

August 10, 2025 | americanbankingnews.com

Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs

July 10, 2025 | accessnewswire.comA

Jaguar Health, Inc.: Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation Supports Research Efforts of Jaguar Health and ...

July 8, 2025 | finanznachrichten.de

Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation (INIA) Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health and CNS Indications of Coca

July 8, 2025 | accessnewswire.comA

Jaguar Health Inc News (JAGX) - Investing.com

July 2, 2025 | investing.com

Proof-of-Concept Results Show Jaguar Health’s Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient

July 1, 2025 | azcentral.comA

Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient

June 30, 2025 | accessnewswire.comA

JAGX Jaguar Health, Inc. - Seeking Alpha

June 27, 2025 | seekingalpha.com

Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset

June 26, 2025 | accessnewswire.comA

Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs

June 25, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYTO, EVAX, DRMA, and JAGX Company Descriptions

Altamira Therapeutics NASDAQ:CYTO

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.

Dermata Therapeutics NASDAQ:DRMA

$5.46 +0.05 (+0.94%)

As of 02:53 PM Eastern

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Evaxion A/S NASDAQ:EVAX

$3.06 +0.11 (+3.86%)

As of 03:04 PM Eastern

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Jaguar Animal Health NASDAQ:JAGX

$1.86 -0.01 (-0.53%)

As of 03:06 PM Eastern

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time